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Abstract
Background: Direct access to genomic information has the potential to transform cancer risk counseling. We
measured the impact of direct-to-consumer genomic risk information on changes to perceived risk (ΔPR) of breast,
prostate, colorectal and lung cancer among personal genomic testing (PGT) customers. We hypothesized that ΔPR
would reflect directionality of risk estimates, attenuate with time, and be modified by participant characteristics.
Methods: Pathway Genomics and 23andMe customers were surveyed prior to receiving PGT results, and 2 weeks
and 6 months post-results. For each cancer, PR was measured on a 5-point ordinal scale from “much lower than
average” to “much higher than average.” PGT results, based on genotyping of common genetic variants, were
dichotomized as elevated or average risk. The relationship between risk estimate and ΔPR was evaluated with linear
regression; generalized estimating equations modeled this relationship over time.
Results: With the exception of lung cancer (for which ΔPR was positive regardless of result), elevated risk results
were significantly associated with positive ΔPR, and average risk results with negative ΔPR (e.g., prostate cancer,
2 weeks: least squares-adjusted ΔPR = 0.77 for elevated risk versus −0.21 for average risk; p-valuedifference < 0.0001)
among 1154 participants. Large changes were rare: for each cancer, <4 % of participants overall reported a ΔPR
of ±3 or more units. Effect modification by age, cancer family history, and baseline interest was observed for breast,
colorectal, and lung cancer, respectively. A pattern of decreasing impact on ΔPR over time was consistently
observed, but this trend was significant only in the case of colorectal cancer.
Conclusions: We have quantified the effect on consumer risk perception of returning genetic-based cancer risk
information directly to consumers without clinician mediation. Provided via PGT, this information has a measurable
but modest effect on perceived cancer risk, and one that is in some cases modified by consumers’ non-genetic risk
context. Our observations of modest marginal effect sizes, infrequent extreme changes in perceived risk, and a
pattern of diminishing impact with time, suggest that the ability of PGT to effect changes to cancer screening and
prevention behaviors may be limited by relatively small changes to perceived risk.
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Background
Direct-to-consumer personal genomic testing (PGT) is
distinct from clinical genetic testing in both its
process and goals: whereas clinical testing is typically
ordered as part of a medical evaluation to identify
highly penetrant mutations associated with rare phe-
notypes (e.g., Lynch syndrome), PGT provides gener-
ally healthy consumers with information about
common single nucleotide polymorphisms (SNPs) that
have been associated with multifactorial diseases (e.g.,
colorectal cancer). PGT is not diagnostic, but pro-
vides risk information to a consumer that he or she
may consider in making health-related decisions, such
as when to begin cancer screening (e.g., colonoscopy).
The possibility that PGT could impact health services
has prompted professional organizations [1, 2], including
the American Society of Clinical Oncology [3], to call
for research in this area, and a considerable body of re-
search on the consumer and physician experience of
PGT now exists [4]. After nearly a decade of such re-
search, however, PGT continues to be controversial [5–
8], and in November 2013, the United States Food and
Drug Administration (FDA) ordered 23andMe, Inc. [9]
(23andMe)—a leading PGT provider—to cease market-
ing of their health-related PGT services. Since then,
23andMe’s health-related services have not been rein-
stated in the United States, but in 2014 the company
launched similar services in both Canada [10] and the
United Kingdom [11].
Here, we have analyzed the impact of PGT-derived
cancer risk information on consumers’ perceived risk of
four cancers for which screening is possible (breast,
prostate, colorectal, and lung) using data from the Im-
pact of Personal Genomics (PGen) Study [12]. To date,
there have been no empirical studies focused specifically
on PGT for cancer risk, despite the fact that it has the
potential to alter the landscape of cancer genetic coun-
seling by improving the precision of individual risk esti-
mates [13, 14], increasing demand for cancer screening
[15], and shifting control of genetic screening from phy-
sicians to consumers [16].
Due to the importance of perceived disease risk in
numerous prominent theories of health behavior [17],
we chose as the primary outcome measure in our
analyses change in perceived risk (ΔPR) of each can-
cer from baseline (pre-results) to 2 weeks and
6 months post-results. We hypothesized that: ΔPR for
each cancer would be significantly associated with
PGT risk estimate at both follow-up time points; dir-
ectionality of ΔPR would reflect direction of PGT risk
estimate relative to average population risk; magni-
tude of ΔPR would attenuate with time; and the effect
of PGT risk estimate on ΔPR would be modified by
baseline participant characteristics.
Methods
The impact of Personal Genomics (PGen) study
The PGen Study is a collaboration between academic
researchers and two PGT companies, and the academic-
industry partnership [18] and recruitment and data
collection methods [12] have been described in detail
elsewhere. Briefly, new customers of 23andMe and Path-
way Genomics [19] (Pathway) were recruited online after
placing an order for direct-to-consumer PGT between
March and July 2012. Following an online consent
process, participants were invited to three web-based
surveys administered by Survey Sciences Group, LLC
(Ann Arbor, Michigan): at baseline, after they had or-
dered testing but prior to receiving their results (BL);
2 weeks after viewing their results (2 W); and 6 months
after viewing their results (6 M). Results were returned
to customers according to the standard practice of each
company and were linked to survey data at the end of
survey administration. In total, 1464 participants com-
pleted the baseline survey and were eligible for follow-
up; of these, 1046 (71.4 %) and 1042 (71.2 %) submitted
the 2-week and 6-month surveys, respectively. Institu-
tional approval was obtained from the Partners Human
Research Committee and the University of Michigan
School of Public Health Institutional Review Board.
Exposure variables
Participants received a genetic risk estimate, based on
genotyping of multiple SNPs (Additional file 1: Table
S1), for each of breast (women only), prostate (men
only), colorectal and lung cancer. 23andMe customers
were provided with a report that included: (1) a baseline,
10-year age-adjusted risk of each cancer, assigned prior
to genetic testing; (2) an age-adjusted relative risk for
each cancer based on the customer’s genetic profile; and
(3) a revised 10-year age-adjusted risk of each cancer
computed by multiplying together values (1) and (2).
Risk estimates were additionally adjusted for biological
sex in the case of colorectal cancer (Additional file 1:
Table S2). These results were presented in the form of
two diagrams each with 100 human figures, the first
with a proportion shaded in to represent the general
population risk (quantity 1, above), and the second with
a proportion shaded in to represent the genetics-
adjusted risk (quantity 3, above).
Pathway customers generally received results on a 5-
category scale corresponding to increasing RR of disease;
however, in the case of the four cancers being studied,
all results provided were in either the second lowest cat-
egory (Learn More: “Your genetic profile gives you an
average predisposition to these conditions, and most
people fall in this category. You should focus on disease
prevention, learn about your family history and how life-
style choices influence disease onset”) or the middle
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category (Be Proactive: “Your genetic profile shows in-
creased susceptibility for these health conditions. You
should make an effort to learn the warning signs, con-
tributing lifestyle factors, and your family history for
these conditions. Speak with your doctor about develop-
ing a prevention plan.”) (Additional file 1: Table S3).
In order to harmonize genetic risk information across
companies, a threshold RR level was selected to distin-
guish elevated from average genetic risk. This process
was undertaken during the data cleaning stage of the
PGen Study and prior to any analysis of study data, in-
cluding but not limited to the analysis presented here.
Based upon consideration of their results reporting stan-
dards, each company advised PGen Study researchers on
determination of this threshold. A threshold of RR ≥ 1.2
to distinguish elevated genetic risk was ultimately
chosen based on three considerations: 1) 23andMe rep-
resentatives indicated that the company generally con-
siders average risk as within 20 % of general population
risk; 2) Pathway representatives agreed that this thresh-
old would in most instances match well the cut-point
between their risk categories of “Learn More” and “Be
Proactive”; and 3) PGen Study researchers agreed that in
the context of DTC-PGT and genetic testing of com-
mon, low-penetrance variants, a RR ≥ 1.2 was appro-
priately indicative of an elevated genetic risk. Results
across both companies were therefore dichotomized
into two categories: average genetic risk (RR < 1.2;
“Learn More” category) and elevated genetic risk
(RR ≥ 1.2; “Be Proactive” category). Due to the
restricted distribution of Pathway results, we were un-
able to discriminate in our analyses between average
and reduced genetic risk results.
Outcome variables
Participants were asked on all surveys to rate their
chances of developing each type of cancer “compared to
the average [man or woman] of [the same] age.” Re-
sponses were recorded on a 5-point risk perception scale
ranging from much lower than average (1) to much
higher than average (5); [20, 21] alternatively, partici-
pants could select “I have been diagnosed with this con-
dition.” Perceived risk (PR) was operationalized as a
continuous variable, with each step on the 5-point scale
corresponding to a 1 unit change.
Other variables
Age, race/ethnicity [22], gender, annual household in-
come, highest education level, interest in cancer-specific
PGT results (‘very interested,’ ‘somewhat interested,’ ‘not
at all interested,’ for each cancer type), smoking status
(‘never,’ ‘past,’ or ‘current’), and cancer family history
were measured at baseline. Participants were asked to
report on each blood relative with cancer, including both
maternal and paternal families, and to indicate the type
of cancer diagnosed in that relative. A series of condi-
tional survey branches were used to obtain this informa-
tion: e.g., (1) “Which of your blood relatives have ever
had [cancer]?” (choose all that apply from list of relation
types); (2) if “brother or sister” is selected, participant
would be prompted with “Please select the type(s) of
[cancer] that [a brother or sister] has had” (choose all
that apply from a list of cancer types). Additional condi-
tional branches were generated for each relative reported
to have a history of cancer, but we did not collect infor-
mation on age at diagnosis or family size. Using this
data, a site-specific, 3-level ordinal family history vari-
able was created for each of the four cancers, with levels
corresponding to “no family history,” “family history in
2nd degree relative(s) only,” and “family history in 1st
degree relative(s).” A general cancer family history vari-
able, inclusive of all cancer types, was created in the
same way. Use of cancer screening services since under-
going PGT was queried at 6 months with questions from
the 2011 Behavioral Risk Factor Surveillance System
Questionnaire, modified to reflect a 6-month window of
interest [23].
Statistical analyses
Data for this analysis were obtained from 1155 partici-
pants who completed the BL survey plus at least one
follow-up survey. Primary analysis samples were re-
stricted to participants with an available genetic risk esti-
mate for the cancer being studied; no missing data for
BL-, 2 W-, or 6 M-PR (as necessary) for that cancer; and
no reported diagnosis of the cancer being studied at any
time during the data collection period.
We first performed linear regressions of change in PR
from BL to 2 W (ΔPR2W) and from BL to 6 M (ΔPR6M)
for each cancer. Analyses were adjusted for BL-PR, age,
gender, race (White vs. non-White), Hispanic/Latino
ethnicity, education (4 categories), smoking status (lung
cancer only), and testing company; cancer family history
and interest in cancer-specific results were evaluated as
possible confounders. From the resulting linear regres-
sion models, least squares-adjusted mean ΔPRs were
computed, stratified by genetic risk estimate (elevated
risk versus average risk).
We used generalized estimation equations (GEEs) to
account for the expected correlation between ΔPR2W
and ΔPR6M and to evaluate the hypothesis that the
effect of genetic risk estimate on ΔPR varied by
follow-up time. In each model we included an inter-
action term between follow-up survey time and
genetic risk estimate, and used a Wald test of signifi-
cance to evaluate our hypothesis.
We next investigated effect modification by baseline
participant characteristics. In order to maximize power,
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we conducted interaction analyses in the relevant 2 W
follow-up samples, which had the smallest amount of
missing data, and used the corresponding linear regres-
sion model (described above). Wald tests of significance
were used to evaluate, in turn, interaction terms between
genetic risk estimate and each of the following: baseline
interest, age, gender (for colorectal and lung cancers),
cancer family history, and smoking status (lung cancer
only). Significant interaction terms were retained, and a
final regression model was obtained for each cancer.
From these, least squares-adjusted mean ΔPRs, stratified
by genetic risk estimate and significant effect modifiers,
were computed.
Sensitivity analyses
To assess the impact on our results of the decision to
use linear regression modeling of ΔPR, which assumes a
constant effect of genetic risk information on any 1-unit
change in PR, we alternately performed each of the 2 W
regression analyses using generalized logistic regression
with ΔPR = 0 as the reference category for the outcome.
To evaluate our selection of relative risk rather than ab-
solute risk as the main predictor of ΔPR, we evaluated
the correlation between RR and absolute risk results for
each cancer. We also transformed RR into a four-
category variable corresponding to quartiles (RRq), per-
formed a linear trend test of RRq in the ΔPR6M linear
regression models for each cancer, and then evaluated
RRq as a categorical variable to observe the pattern of
effect across quartiles. Because absolute risk and RR
values were not available for Pathway Genomics partici-
pants, they were excluded from these analyses.
To evaluate the possibility that ΔPR was affected by
cancer screening undertaken as a result of PGT, we re-
peated the ΔPR6M linear regressions, excluding anyone
who had received screening for the relevant cancer since
receiving their results. To evaluate the impact of inform-
ative censoring due to missing PR data at follow-up, we
repeated the ΔPR6M linear regressions on a pseudo-
population created using inverse probability-weighting
(IPW) for missing data [24].
All analyses were conducted using SAS software (ver-
sion 9.3; SAS Institute, Cary, NC), and models were
fitted using PROC GLM (linear regressions) and PROC
GENMOD (longitudinal analyses and IPW). Statistical
significance for all analyses was set at p < 0.05.
Results
Participants
One participant was excluded from all analyses due to
missing gender data. For each cancer, between 6.2 % and
14.5 % of participants were excluded from analysis due
to missing baseline PR, missing genetic risk data, or a
cancer diagnosis prior to or during the data collection
period. Sample sizes for each cancer-specific analysis are
presented in Table 1.
Subjects reporting cancer-specific PRs were similar in
most cases with respect to age, gender, education,
income, race, smoking status, and general cancer family
history (Table 2), although female participants reporting
breast cancer PR reported significantly lower levels of
education (X3
2 = 8.2, p = 0.040) and income (X4
2 = 20.7,
p = 0.0004) and greater frequency of any cancer family
history (X3
2 = 8.2, p = 0.016) than male participants
reporting prostate cancer PR. Baseline PR, interest in
cancer-specific PGT results, and reported cancer-
specific family history showed considerable variation
across samples: for example, only 40.9 % of partici-
pants reporting lung cancer PR were ‘very interested’
in learning their genetic risk of lung cancer, while
66.6 % of participants reporting breast cancer PR
were ‘very interested’ in learning their genetic risk of
breast cancer.
Change in perceived risk of cancer
Elevated risk results were least frequent for breast cancer
(10.8 % in 2 W follow-up samples; 9.6 % in 6 M follow-
up samples) and most frequent for colorectal cancer
(24.9 %; 24.3 %) (Table 3). Compared to participants
who received elevated risk results, those who received
average risk results more frequently indicated no change
in perceived risk of a particular cancer. In all cases, an
increase in perceived risk of x units among participants
who received elevated risk results was more common
than a decrease in perceived risk of x units among par-
ticipants who received average risk results. Changes to
PR, stratified by cancer and genetic risk result, are
shown in Table 3. Overall, changes of > 2 units (PR cat-
egories) were infrequent: at 2 W follow-up, 8 (1.4 %), 12








700 454 1154 1154
Eligible survey
responsesa
649 388 1082 1080
2 W linear
regressionb
576 354 969 966
6 M linear
regressionc
565 343 947 945
Longitudinal
analysisd
500 314 847 844
2 W 2-week follow-up, 6 M 6-month follow-up
aNo missing data for cancer-specific genetic risk result or baseline perceived
risk; no reported cancer-specific diagnosis during data collection period
bEligible survey responses, with available data for 2 W perceived risk
cEligible survey responses, with available data for 6 M perceived risk
dEligible survey responses, with available data for both 2 W and 6 M
perceived risk
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(3.4 %), 16 (1.7 %), and 19 (2.0 %) participants reported
changes of ±3 or ±4 units for breast, prostate, colorectal,
and lung cancer, respectively. At 6 M follow-up, these same
values were 9 (1.6 %), 8 (2.3 %), 8 (0.8 %), and 24 (2.5 %).
Change in perceived risk and genetic risk results
At both follow-up time points, and for all four cancers,
multivariate linear regression revealed a significant effect
of genetic risk estimate on ΔPR (Table 4). In general,
Table 2 Characteristics of PGen study participants included in at least one linear regression analysis for change in perceived risk of
cancer
Breast (n = 641) Prostate (n = 383) Colorectal (n = 1069) Lung (n = 1067)
No. % No. % No. % No. %
Female gender 641 100.0 0 0.0 646 60.4 647 60.6
Non-white race 90 14.0 43 11.2 145 13.6 144 13.5
Hispanic/latino ethnicity 23 3.6 20 5.2 39 3.7 39 3.7
Highest level of education
No college degree 152 23.7 64 16.7 224 20.9 223 20.9
College degree only 194 30.3 121 31.6 327 30.6 326 30.6
Some graduate school 219 34.2 139 36.3 375 35.1 375 35.1
Doctoral-level degree 76 11.8 59 15.4 143 13.4 143 13.4
Annual household income
< $40,000 118 18.4 55 14.4 177 16.5 176 16.5
$40,000–$69,999 128 20.0 55 14.4 192 17.9 192 18.0
$70,000–$99,999 135 21.1 75 19.6 223 20.9 223 20.9
$100,000–$199,999 193 30.1 126 32.9 329 30.9 331 31.0
≥ $200,000 58 9.0 66 17.2 133 12.4 130 12.2
Not reported 9 1.4 6 1.5 15 1.4 15 1.4
Any cancer family history
Affected FDR(s) 296 46.2 167 43.6 489 45.7 488 45.8
Affected SDR(s) only 219 34.2 116 30.3 345 32.3 345 32.3
No affected FDR/SDR(s) 116 18.1 99 25.8 223 20.9 222 20.8
Not reported 10 1.5 1 0.3 12 1.1 12 1.1
Specific cancer family historya
Affected FDR(s) 84 13.1 29 7.6 72 6.8 65 6.1
Affected SDR(s) only 137 21.4 21 5.5 138 12.9 139 13.0
No affected FDR/SDR(s) 410 64.0 332 86.7 847 79.2 851 79.8
Not reported 10 1.5 1 0.2 12 1.1 12 1.1
Interest in cancer-specific PGT
Not at all interested 37 5.8 19 5.0 120 11.2 209 19.6
Somewhat interested 177 27.6 136 35.5 392 36.7 421 39.5
Very interested 427 66.6 228 59.5 557 52.1 437 40.9
Pathway customers 290 45.2 115 30.0 415 38.8 414 38.8
Age, years
Mean ± standard deviation 46.8 ± 14.9 45.7 ± 16.2 47.1 ± 15.7 47.1 ± 15.7
Range 19, 92 19, 91 19, 94 19, 94
Baseline perceived riskb
Mean ± standard deviation 2.8 ± 1.0 2.9 ± 0.9 2.7 ± 1.0 2.3 ± 1.0
Range 1, 5 1, 5 1, 5 1, 5
FDR first-degree relative, SDR second-degree relative, PGT personal genomic testing
aOnly includes reported cases of the type of cancer being studied
bFor the specific cancer being studied, rated from “much below average” (1) to “much higher than average” (5)
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Table 3 Distribution of changes in perceived risk from baseline to follow-up, stratified by cancer, genetic result, and follow-up time
Breast Prostate Colorectal Lung
Genetic risk result Average Elevated Average Elevated Average Elevated Average Elevated
2-week follow-up
Frequency, n (%) 514 (89.2) 62 (10.8) 278 (78.5) 76 (21.5) 728 (75.1) 241 (24.9) 781 (80.8) 185 (19.2)
Unit change in perceived risk (%)
−4 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0
−3 0.6 0.0 1.4 0.0 0.7 0.4 0.5 0.0
−2 6.8 6.5 5.0 1.3 3.6 0.8 2.7 1.6
−1 23.7 6.5 26.6 14.5 22.7 11.6 19.1 11.4
0 51.6 37.1 51.1 25.0 50.0 38.2 47.0 37.3
+ 1 14.0 35.5 14.0 35.5 19.2 35.7 24.2 31.9
+ 2 3.3 14.5 1.4 14.5 3.7 9.5 5.9 12.4
+ 3 0.0 6.5 0.4 7.9 0.0 3.7 0.5 5.4
+ 4 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0
6-month follow-up
Frequency, n (%) 511 (90.4) 54 (9.6) 266 (77.6) 77 (22.4) 717 (75.7) 230 (24.3) 773 (81.8) 172 (18.2)
Unit change in perceived risk (%)
−4 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0
−3 0.6 1.9 0.8 0.0 0.1 0.0 0.7 0.0
−2 6.7 0.0 4.9 5.2 4.6 1.7 2.7 1.7
−1 23.1 18.5 26.3 10.4 21.5 15.7 18.4 12.8
0 50.9 33.3 51.5 32.5 52.4 40.9 48.0 41.3
+1 13.9 27.8 14.7 33.8 16.9 30.0 22.9 27.9
+2 4.5 13.0 1.9 10.4 4.2 9.6 6.3 10.5
+3 0.4 1.9 0.0 5.2 0.1 2.2 0.8 5.8
+4 0.0 3.7 0.0 2.6 0.1 0.0 0.1 0.0
Table 4 Linear regression and generalized estimating equation models for effect of genetic risk estimate on change in perceived
risk of cancer
Breast Prostate Colorectal Lungc
Change in perceived risk: baseline to 2Wa
Elevated risk result: LS mean (95 % CI) 0.61 (0.42, 0.79) 0.77 (0.58, 0.95) 0.50 (0.41, 0.60) 0.62 (0.49, 0.75)
Average risk result: LS mean (95 % CI) −0.20 (−0.27, −0.14) −0.21 (−0.31, −0.11) −0.05 (−0.10, 0.01) 0.18 (0.10, 0.27)
LS mean difference (95 % CI) 0.81 (0.62, 1.00) 0.97 (0.76, 1.19) 0.55 (0.44, 0.66) 0.44 (0.31, 0.57)
p-valueDifference <0.0001 <0.0001 <0.0001 <0.0001
Change in perceived risk: baseline to 6Ma
Elevated risk result: LS mean (95 % CI) 0.53 (0.32, 0.74) 0.51 (0.32, 0.69) 0.33 (0.24, 0.43) 0.58 (0.44, 0.72)
Average risk result: LS mean (95 % CI) −0.15 (−0.22, −0.07) −0.14 (−0.24, −0.04) −0.04 (−0.09, 0.02) 0.22 (0.13, 0.31)
LS mean difference (95 % CI) 0.68 (0.46, 0.90) 0.65 (0.43, 0.86) 0.37 (0.26, 0.48) 0.36 (0.22, 0.49)
p-valueDifference <0.0001 <0.0001 <0.0001 <0.0001
GEE Model: ΔPRb
Elevated risk result: β ± SE (p-value) 0.68 ± 0.29 (0.02) 1.06 ± 0.20 (<0.0001) 0.79 ± 0.11 (<0.0001) 0.59 ± 0.13 (<0.0001)
Elevated risk result*survey: β ± SE (p-value) 0.06 ± 0.19 (0.76) −0.15 ± 0.11 (0.17) −0.20 ± 0.07 (0.0027) −0.11 ± 0.08 (0.17)
2 W 2-week follow-up, 6 M 6-month follow-up, LS least squares adjusted, CI confidence interval, SE standard error
aAdjusted for baseline perceived risk, age, gender, race/ethnicity, education, and company
bAdjusted for baseline perceived risk, age, gender, race/ethnicity, education, and company, with result*survey interaction term
cMultivariate lung cancer analyses additionally adjusted for smoking status
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mean ΔPR among those receiving an elevated risk result
(range = 0.33–0.77 units) was greater in magnitude than
mean ΔPR among those receiving an average risk result
(range = 0.04–0.22 units). Mean ΔPR for lung cancer
was positive, regardless of genetic risk estimate, at both
time points. For all other cancers, mean ΔPR was posi-
tive among those receiving an elevated risk result and
negative among those receiving an average risk result.
Effect estimates did not change in models that included
adjustment for general cancer family history, specific
cancer family history, or baseline interest in PGT cancer
risk results.
A trend of greater effect sizes at 2 W follow-up com-
pared to 6 M follow-up was apparent for all cancers;
however, GEE modeling of the survey by genetic risk
estimate interaction found evidence for significant effect
modification by follow-up time only in the case of colo-
rectal cancer (Table 4).
Effect modification
Increasing age was associated with a significantly at-
tenuated effect of genetic risk estimate on ΔPR of
breast cancer at 2-week follow-up (pinteraction =
0.0467). Among women in the lowest age group by
decile, an elevated risk result was associated with a
1.12 unit greater ΔPR than an average risk result
(95 % CI = 0.78, 1.46). For each decile increase in age
category, this difference decreased by an average of
0.08 units (0.007, 0.14). A similar trend was observed
for prostate cancer, but the interaction term between
risk result and age was non-significant (p = 0.0591).
Family history of cancer was a significant modifier of
the effect of genetic risk estimate on ΔPR of colorectal
cancer at 2-week follow-up (pinteraction = 0.0093). Among
participants who reported no history of cancer in first-
or second-degree relative, an elevated risk result was as-
sociated with a 0.26 unit greater ΔPR than an average
risk result (95 % CI = 0.03, 0.50); however, among partic-
ipants reporting a positive family history of cancer, an
elevated risk result was associated with a 0.61 unit greater
ΔPR than an average risk result (95 % CI = 0.49, 0.73). Ad-
justed mean ΔPR values, stratified by family history status
and genetic risk result are shown in Fig. 1a.
Baseline interest in lung cancer genetic risk informa-
tion was a significant modifier of the effect of genetic
risk estimate on ΔPR of lung cancer (p = 0.0108). Among
participants who indicated low interest in these results
at baseline, there was no significant difference in the
impact of an elevated risk result and an average risk
result on ΔPR of lung cancer (mean difference = 0.14,
95 % CI = −0.12, 0.41). An elevated risk result was,
however, associated with a significantly greater ΔPR than
an average risk result among those participants who indi-
cated a moderate or high interest in these results at
baseline (mean difference = 0.53, 95 % CI = 0.39, 0.67).
(“Moderate” and “High” interest categories were collapsed
for presentation of the data because effect estimates and
confidence intervals were identical in these two groups.)
Adjusted mean ΔPR values, stratified by interest and gen-
etic risk result are shown in Fig. 1b. There was no evi-
dence of effect modification by smoking status; however,
we noted a strong correlation between smoking status
(never/former/current) and baseline interest in lung can-
cer genetic risk information (low/moderate/high), with
58 % of current smokers, 50 % of former smokers, and
34 % of never smokers indicating high interest in these
results (X2
2 = 28.9, p < 0.0001).
Sensitivity analyses
The results of modeling ΔPR as a categorical variable
are presented in Additional file 1: Table S4. The small
number of people who reported large changes in PR
made odds ratio estimates unstable for these categories
(ΔPR > +2 or < −2) unstable; however, the results of
using generalized logistic regression were qualitatively
consistent with the results from our main linear regres-
sion models. A clear pattern of greater odds of an in-
crease in PR—and lower odds of a decrease in PR—with
an elevated risk result was observed, and these effects
were significant across all cancers in the categories of
ΔPR = +1 and ΔPR = +2, and across breast, colorectal,
and lung cancer for the ΔPR = −1 category.
All 23andMe participants of the same sex were
assigned the same cancer-specific population risk
values; therefore, absolute risk and RR values were
perfectly correlated after stratification by sex. Among
23andMe participants, the trend of effect across quar-
tiles of RR suggested that the use of RR > 1.2 as the
threshold for increased genetic risk was appropriate.
For lung cancer, the effect of a reduced risk estimate
was not significantly different from that of an average
risk estimate; however, a significant difference in ΔPR
between those who received a reduced risk estimate
and those who received an average risk estimate was
observed for breast, prostate, and colorectal cancer
(Additional file 1: Table S5).
Among participants in the ΔPR6M analyses, 311
(55.0 % of 565) reported some type of breast cancer
screening (mammography, breast MRI, or clinical breast
exam) since receiving their PGT results; 78 (22.7 % of
343) reported PSA testing; 87 (9.1 % of 947) reported a
colonoscopy; and 14 (1.5 % of 945) reported lung cancer
screening. Excluding screened participants from the lin-
ear regressions presented in Table IV made no substan-
tial difference to the effect estimates or mean ΔPRs
(Additional file 1: Table S6).
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Missing data for PR-6 M resulted in censoring of
11.6–12.9 % of participants from each ΔPR6M linear re-
gression sample. IP weighting to adjust for this missing
data revealed no significant differences in effect esti-
mates (Additional file 1: Table S6).
Discussion
We have shown that commercial PGT risk estimates
based on common, low-penetrance SNPs have a modest
but significant effect on perceived risk of breast, pros-
tate, colorectal, and lung cancers. Directionality of effect
was typically as expected, with elevated risk results cor-
responding to an increase in perceived cancer risk, and
average risk results corresponding to unchanged or
slightly lower perceived risk. Lung cancer proved excep-
tional in this respect: regardless of PGT result, we ob-
served a mean increase in perceived risk of lung cancer
following PGT. One explanation for this finding is that
consumers may not have known, prior to undergoing
PGT, that lung cancer risk includes not only an environ-
mental component, but also a genetic component.
Receiving a genetic-based risk prediction for lung
cancer, then, may have suggested to consumers that
they were at risk for lung cancer even if they did not
have typical risk factors, such as smoking history and
occupational exposures.
On the other hand, stratification by baseline interest
revealed that the effect of genetic risk information for
lung cancer was significantly greater among consumers
who expressed (prior to receiving their results) an inter-
est in obtaining this particular information about them-
selves than among consumers who were “not at all
interested” in learning their genetic risk of lung cancer.
Although there was no statistical evidence of effect
modification by smoking status, we did observe a strong
positive correlation between baseline interest in lung
cancer genetic risk information and smoking history.
Thus, one interpretation of the observed effect modifica-
tion by interest is that smoking (or other carcinogenic
exposure) history drives baseline interest in lung cancer
genetic risk information, which in turn modifies con-
sumers’ responses to receiving this information.
These findings highlight a complex relationship
between genetic information and risk perception, and
suggest that consumers incorporate both genetic and
non-genetic risk factors into their personal estimation of
risk. This interpretation is further supported by the re-
sults of effect modification analyses for breast and colo-
rectal cancer: Older women, in whom the impact of
genetic risk information was attenuated compared to
younger women, have more information on which to
base their perceived risk of breast cancer (e.g., results of
prior breast screening), and may be aware that non-
genetic factors (e.g., age) are more important compo-
nents of their risk than the information provided by
PGT. Conversely, in the case of colorectal cancer, for
which the impact of genetic risk information was greater
among those consumers with a positive family history of
cancer than those without, the presence of a family his-
tory of cancer may lead consumers to put greater stock
in their PGT results, since they already have independ-
ent evidence of “genetic risk” of cancer.
The relationship between genetic information and risk
perception is likely further complicated by the method
a b
Fig. 1 Modifiers of the effect of genetic risk estimate on change in perceived risk (ΔPR) of cancer. a. Mean ΔPR of colorectal cancer, stratified by
cancer family history status. An average risk result was associated with a non-significant mean ΔPR of −0.002 (95 % CI = −0.12, 0.11) in participants
reporting no family history of cancer, and a non-significant mean ΔPR of −0.05 (−0.12, 0.007) in those reporting a positive family history. An elevated
risk result was associated with a mean ΔPR of 0.26 (0.06, 0.47) in the absence of family history, and a mean ΔPR of 0.56 (0.45, 0.66) in the presence of
a family history (pinteraction = 0.0093). b. Mean ΔPR of lung cancer, stratified by baseline interest in lung cancer risk results. An average risk
result was associated with a non-significant mean ΔPR of 0.11 (−0.03, 0.25) in participants who expressed low interest in lung cancer risk
information at baseline, and a mean ΔPR of 0.20 (0.11, 0.29) in those who expressed a moderate or high interest in this information at
baseline. An elevated risk result was associated with a mean ΔPR of 0.26 (0.01, 0.50) given low interest, and a mean ΔPR of 0.73 (0.59,
0.88) given moderate or high interest (pinteraction = 0.0434). Error bars represent standard error of the mean
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in which this information is communicated to con-
sumers. Here, each company presented risk information
in a different way: for example, 23andMe relied on a vis-
ual representation of risk as a proportion of persons,
while Pathway presented consumers with a color-coded
hierarchy of risk categories. These differences in risk
presentation are not expected to lead to confounding
after adjustment for PGT company; however, it is pos-
sible that the effect of a genetic risk estimate on per-
ceived risk could be attenuated—or magnified—by the
way in which the risk is described to the consumer.
Similarly, the choice of perceived risk scale may impact
the magnitude of effect observed. If, for example, partici-
pants were asked to report their perceived risk as a per-
centage from 0 to 100, an analysis of change in
perceived risk might have greater precision compared to
our analysis, where perceived risk was measured on a 5-
point scale.
Elucidating the relationship between genetic risk infor-
mation and perceived risk may represent one step to-
wards understanding the link between genetic risk
information and health behavior changes, and commer-
cial PGT presents an opportunity to study this relation-
ship before SNP-based risk prediction moves into the
clinic. PGT for cancer is particularly well-suited to such
study because of broad public awareness of cancer risk
factors [25] and prevention strategies [26], and the
potential for PGT to impact demand for cancer screen-
ing services.
Perceived risk has been studied extensively in the con-
text of clinical genetic testing for high-penetrance, Men-
delian cancer syndromes [27, 28]. In this setting,
findings include: higher perceived risk and increased
colorectal cancer screening rates following a positive
genetic test for Lynch syndrome; [29] lower perceived
risk in non-carriers compared to carriers after testing for
Lynch syndrome and Hereditary Breast and Ovarian
Cancer syndrome; [30, 31] and attenuation of effect on
perceived risk at long-term follow-up [27]. Our work,
however, marks the first comprehensive study of per-
ceived risk of cancer in the context of PGT, which differs
from clinical genetic testing with respect to the genetic
data on which results are based, how results are pro-
vided (online vs. discussion with a clinician) and to
whom results are given (the general population vs. high-
risk clinic patients). Of note, in our study of a non-
clinical population, cancer family history and baseline
interest in cancer risk results (each of which are likely to
be stronger in high-risk clinic patients) were not signifi-
cant predictors of change in perceived risk, and adjust-
ment for these factors did not impact estimates of the
effect of genetic risk information on perceived risk.
The question of how consumers ought to respond to
their PGT results remains unresolved: [32] critics of
PGT note that although the SNPs evaluated by PGT are
validated with respect to disease association at the popu-
lation level, their clinical utility is unknown [33], and
computed risk estimates are calculated in different ways
by different PGT companies [34]. If PGT-derived risk
estimates inappropriately stimulate surveillance, then
PGT could lead to unnecessary use of health services
and iatrogenic complications [15]. Of note here is that
large changes to perceived risk (±3 or more units) were
infrequent in our study, suggesting that PGT may have
limited potential to prompt meaningful health behavior
changes (either positive or negative). Moreover, we ob-
served a pattern of attenuated effect over time, a finding
consistent with previous studies of perceived risk in the
clinical genetics context (see previous paragraph and
Senay and Kaphingst’s review of “anchoring-and-adjust-
ment bias” [35]). This attenuation of effect—significant
in the case of colorectal cancer, and non-significant but
particularly suggestive in the smaller breast and prostate
cancer samples—leaves open the possibility that per-
ceived cancer risk among PGT consumers may ultim-
ately revert to pre-PGT levels. If PGT is to prompt
substantial changes to use of cancer screening services,
our findings suggest that these changes may be most
likely to occur shortly following PGT, and will become
increasingly less likely with time since testing; analyses
of PGen Study data are currently underway to investi-
gate the impact of PGT on cancer screening.
Strengths of our study include its large sample size,
consistency of results across four cancers, and robustness
of results in sensitivity analyses. Limitations include those
inherent to voluntary survey data, including the potential
for selection bias. Analyses of effect modification were lim-
ited in power due to sample stratification; thus, response to
PGT could be further influenced by baseline participant
characteristics in ways that are not evident here. We were
also limited in our ability to investigate the impact of re-
ceiving a genetic risk estimate indicating lower than average
cancer risk, although analysis of the 23andMe data alone
suggests that such risk information may be associated with
a decrease in perceived cancer risk. Finally, our findings are
generalizable to consumers obtaining PGT through a
direct-to-consumer model, but not to other forms of gen-
etic testing. PGen Study participants tended to be well-
educated, high-earning, and White; interpretation of gen-
etic risk information, and its impact on risk perception,
may differ in groups without these qualities.
Conclusions
SNP-based genetic risk information for four common types
of cancer, when provided directly to consumers via com-
mercial PGT, has a measurable effect on consumers’ per-
ceived risk of these cancers. However, while perceived risk
is affected in predictable ways at a population level, effect
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modification analyses suggest a complex interplay between
genetic and non-genetic risk information in consumers’ esti-
mation of personal risk. Our findings further suggest that
the effect of PGT on use of cancer screening services and
modification of risk behaviors may be mitigated by the small
magnitude of its effect on risk perception.
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